Specific RITA Modification Produces Hyperselective Cytotoxicity While Maintaining In Vivo Antitumor Efficacy

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Cancer Research

Background:

• The preclinical antitumor agent RITA (2,5-bis[5-hydroxymethyl-2-thienyl] furan) exhibited broad cytotoxicity and acute pulmonary toxicity, hindering its development.
• Development of hyperselective anticancer agents, similar to imatinib, is a key goal in oncology, offering improved therapeutic profiles.

Purpose of the Study:

• To synthesize and evaluate RITA analogs for improved selectivity and reduced toxicity.
• To elucidate the mechanism underlying RITA's broad cytotoxicity and the selectivity of its analogs.

Main Methods:

• Chemical synthesis of RITA analogs with modifications to the heterocyclic scaffold.
• Anticancer activity screening using the NCI 60-cell line panel.
• Development and application of a selectivity index (SI) to quantify agent selectivity.
• Inhibition studies using a SULT1A1 inhibitor.
• Quantum mechanical calculations to assess carbocation formation energy barriers.

Main Results:

• A series of RITA analogs displayed a range of activities, from broadly cytotoxic to hyperselective (SI up to 7.9).
• Hyperselective analogs showed reduced dependence on SULT1A1 expression compared to RITA.
• A strong correlation was observed between calculated energy barriers for carbocation formation and SI.
• Several hyperselective analogs (NSC 773097, 773392, 782846) demonstrated significant in vivo antitumor activity against A498 xenografts.

Conclusions:

• Sulfation by SULT1A1 and subsequent carbocation formation likely contribute to RITA's broad cytotoxicity.
• Hyperselective RITA analogs, with reduced propensity for carbocation formation, offer a promising therapeutic window.
• These findings pave the way for developing safer and more effective anticancer agents based on the RITA scaffold.